Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

Submitted by admin on March 4, 2019 - 9:57am
Source: 
Endpoints
News Tags: 
gene editing
IPOs
ARC nuclease
ARCUS
Precision Biosciences
Headline: 
Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field
snippet: 


CRISPR/Cas9. TALEN. Zinc finger nuclease tech. The ARC nuclease.

You may have heard about those first 3 gene-editing platforms. But what’s an ARC nuclease?

Do Not Allow Advertisers to Use My Personal information